Pingora Partners LLC Acquires New Position in Pfizer Inc. $PFE

Key Points

• Pingora Partners LLC acquired 89,510 Pfizer shares worth approximately $2.16 million during the second quarter, making Pfizer its 18th-largest holding and 1.3% of its portfolio.
• Pfizer exceeded quarterly expectations with adjusted EPS of $0.77 versus the $0.68 consensus and revenue of $15.03 billion versus $14.40 billion estimates; revenue increased 2.6% year over year.
• The stock offers a 6.1% dividend yield, but analysts maintain a consensus “Hold” rating with an average price target of $28.28, reflecting ongoing concerns about patent expirations and the need for pipeline products to restore growth.

Pingora Partners LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 89,510 shares of the biopharmaceutical company's stock, valued at approximately $2,155,000. Pfizer comprises about 1.3% of Pingora Partners LLC's portfolio, making the stock its 18th biggest position.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank bought a new position in shares of Pfizer in the 4th quarter worth $1,830,986,000. Bank of America Corp DE acquired a new stake in shares of Pfizer during the second quarter worth $1,049,602,000. BlackRock Inc. increased its holdings in Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock valued at $12,754,464,000 after purchasing an additional 31,412,883 shares during the last quarter. Morgan Stanley lifted its stake in Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company's stock valued at $2,218,929,000 after buying an additional 14,342,946 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in Pfizer by 38.9% in the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company's stock valued at $1,208,023,000 after buying an additional 13,581,757 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 0.8%

Shares of Pfizer stock opened at $28.33 on Thursday. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75. The business has a 50-day moving average of $25.44 and a two-hundred day moving average of $26.29. The company has a market capitalization of $161.47 billion, a P/E ratio of 37.28 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the firm posted $0.78 earnings per share. Pfizer's revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer's payout ratio is presently 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer has started a European Medicines Agency review for its Lyme disease vaccine. The review is an important regulatory step that could expand Pfizer’s longer-term vaccine portfolio, although it does not guarantee approval or near-term revenue. Pfizer Starts EMA Review For Its Lyme Disease Vaccine
• Positive Sentiment: Recent comparisons with Bristol Myers Squibb suggest Pfizer’s valuation, diversification and oncology portfolio may offer an attractive risk-reward profile. This supports the view that the stock could benefit if new medicines successfully offset declining legacy-product sales. PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
• Positive Sentiment: Analysts are focused on Pfizer’s post-second-quarter pipeline and whether upcoming medicines can reset the company’s growth trajectory. The opportunity is meaningful because Pfizer recently exceeded quarterly earnings and revenue expectations, but execution remains key. How Is Pfizer Shaping Its S&P 500 Pipeline After Q2?
• Neutral Sentiment: Pfizer’s dividend remains appealing to income-oriented investors, but comparisons with Abbott Laboratories emphasize that Pfizer offers more turnaround potential while Abbott has a steadier dividend-growth record and broader diversification. Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
• Neutral Sentiment: Brokerages collectively rate Pfizer “Hold,” indicating that analysts see potential value but lack a strong consensus catalyst for a decisive re-rating. Pfizer Receives Consensus Recommendation of Hold
• Negative Sentiment: Investor caution persists over Pfizer’s need to restore growth before major patent expirations arrive. Articles discussing new medicines frame the pipeline as necessary to counterbalance expected pressure on established products, limiting enthusiasm until launches and approvals produce measurable results. Can New Medicines Reset the Growth Story?

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent analyst reports. BMO Capital Markets lowered their price target on Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, July 13th. Bank of America reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. UBS Group reaffirmed a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. Finally, Weiss Ratings lowered shares of Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $28.28.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source